Biogen Inc. is based in Cambridge. The European Union’s drug regulator denied approval of Biogen’s Alzheimer’s disease drug, made in partnership with Eisai Inc.
The European Union's drug regulator denied approval of Biogen Inc.'s Alzheimer's disease drug, made in partnership with Eisai Inc.
The recommendation to reject the drug, marketed as Leqembi, came on Friday from the Committee for Medicinal Products for Human Use of the European Medicines Agency.
Stream NBC10 Boston news for free, 24/7, wherever you are.
More on this story from Boston Business Journal
Get updates on what's happening in Boston to your inbox with our News Headlines newsletter.
Copyright Boston Business Journal
